Compare CLST & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLST | CVM |
|---|---|---|
| Founded | 1922 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.6M | 53.1M |
| IPO Year | N/A | 1987 |
| Metric | CLST | CVM |
|---|---|---|
| Price | $15.03 | $6.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.6K | ★ 61.1K |
| Earning Date | 01-22-2026 | 01-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $11,340,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.23 | ★ N/A |
| Revenue Growth | ★ 133.67 | N/A |
| 52 Week Low | $10.67 | $1.98 |
| 52 Week High | $15.30 | $32.70 |
| Indicator | CLST | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 68.54 | 40.79 |
| Support Level | $15.00 | $5.56 |
| Resistance Level | $15.00 | $7.80 |
| Average True Range (ATR) | 0.09 | 0.56 |
| MACD | -0.04 | 0.06 |
| Stochastic Oscillator | 95.56 | 32.59 |
Catalyst Bancorp Inc is a bank holding company. Through its subsidiary, which is a federally chartered community-oriented savings bank, it is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources, which are used for the origination of loans. It derives income principally from interest earned on loans and investment securities and, to a lesser extent, from fees received in connection with the origination of loans, service charges on deposit accounts, and other services.
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.